AI DRUG DISCOVERY & DEVELOPMENT SUMMIT

November 18-20
Thomas M. Menino Convention & Exhibition Center

2025 INNOVATION INCUBATOR FINALISTS

MEET THE FINALISTS

The Innovation Incubator is a unique opportunity for visionary startups and early-stage companies to pitch live in front of our entire audience of 500+ industry leaders from pharma, biotech, and potential partners.

Whether harnessing artificial intelligence to transform drug discovery, advancing molecular design, or redefining how new therapies are developed, we aim to spotlight the innovations shaping the future of AI drug discovery and development.

Our distinguished Selection Committee has selected four early-stage start-ups to present this year, each showcasing a bold vision of how technology can accelerate and enhance the path from discovery to patient impact.

MEET THE FINALISTS

2025 SELECTION COMMITTEE

Parthiban Rajasekaran
Innovation Lead
Sanofi

Uli Stilz
Corporate VP, R&ED External Innovation Partners
Novo Nordisk

John Mayfield
SVP BD & Strategy
Flagship Pioneering

Michaela Tolman
Commercial Development Lead for Inflammation & Immunology
Pfizer

FINALIST

anu bio

ABOUT

At AnuBio, we are building foundational models of multicellular systems to enable in silico phenotypic drug discovery. Our approach combines the power of phenotypic screening with the flexibility of computational modeling. To achieve this, we have developed TRAILBLAZER, a revolutionary AI architecture that delivers over 1,000-fold improvement in performance compared to prior methods, allowing us to model the behavior of systems comprising thousands of cells. This platform is particularly effective for diseases with unknown targets or mechanisms of action, as defining a desired phenotype is sufficient for the model to propose treatments.

ADRIAN GRZYBOWSKI
FOUNDER & CSO

Dr. Adrian Grzybowski is the CSO and co-founder of AnuBio, an AI-driven phenotypic drug discovery company pioneering foundational models of the multicellular system for next-generation therapeutics. He got his PhD from the University of Chicago in Cellular and Molecular Biology. Before founding AnuBio, he was a founding scientist at Alamar Biosciences, where he co-invented the world's most sensitive protein assay, helping raise $250M. His work on biparatopic antibodies led to the creation of Attovia ($250M raised). Subsequently, he led the pharma division of Triplebar, where he built the first unbiased, ultra-high-throughput (>100M) phenotypic screening platform for immuno-oncology.

FINALIST

CellVoyant

ABOUT

CellVoyant is a biotechnology company that predicts stem cell differentiation using live cell microscopy and artificial intelligence. We use this approach to optimise and unlock human cell manufacturing for research and therapeutics applications. We aim to understand and solve important health issues, make a long-lasting positive impact on society and change the world.

At the heart of CellVoyant is FateView™, our AI-powered SaaS platform. FateView™ enables biologists to visualize, track, and forecast cell differentiation in real-time. It supports high-throughput experimentation and model inference, combining microscopy, computer vision, cloud infrastructure, and AI to serve cutting-edge stem cell research and manufacturing.

RAFAEL CARAZO SALAS
FOUNDER & CEO

Prof Rafael Carazo Salas has 25-years interdisciplinary quantitative cell and systems biology experience, is a Professor at the University of Bristol's School of Cellular and Molecular Medicine and the CEO and founder of CellVoyant. Prior to founding CellVoyant, Rafael worked at the EMBL Heidelberg, Cancer Research UK, Rockefeller University, the Institute of Biochemistry in Zurich, and the Gurdon Institute in Cambridge. He trained in Montreal, Cambridge, Paris, Heidelberg, London and New York and did his post-doctoral work with Sir Paul Nurse, and had led research groups in ETH Zurich, Cambridge and Bristol.

FINALIST

CAPYBIO

ABOUT

CapyBio is building an AI and genomics powered platform to transform pre-clinical drug discovery and development. A majority of drugs that appear effective in animals fail in humans due to safety or efficacy issues. The solution is high fidelity, human cell-based systems. CapyBio's cell identity platform combines single-cell genomics and AI-guided cell engineering to generate high quality human cells optimizing identity, stability, and scalability. We partner with biopharma companies to build bespoke cell models that power internal R&D pipelines and provide data and protocol products to research tool companies enabling next-generation off-the-shelf solutions.

KUNAL JINDAL
CO-FOUNDER & CTO

Kunal Jindal is the Co-Founder and CTO of CapyBio, leading the development of AI-driven technologies for human cell engineering. He earned his Ph.D. in Molecular Genetics and Genomics from Washington University in St. Louis, where he pioneered methods for single-cell lineage tracing and studying gene regulation. Kunal brings over eight years of research experience at the intersection of genomics, machine learning, and stem cell biology along with a broad perspective on how emerging technologies can advance human health.

FINALIST

MODEL MEDICINES

ABOUT

Model Medicines is an AI-native biotechnology company engineering first-in-class small molecules that target conserved biological choke points driving disease. Its proprietary GALILEO™ platform integrates generative chemistry, multimodal modeling, and novel target discovery to create safe, oral therapeutics across infectious disease, oncology, and inflammation. The company discovered MDL-001, a direct-acting, non-nucleoside broad-spectrum antiviral, and MDL-4101, a selective BRD4 BD1/BD2 inhibitor with no BRD2/3 activity. By uniting large-scale computation with experimental validation, Model Medicines is advancing a new generation of precision-engineered therapeutics that redefine what is possible in modern drug discovery. Learn more at www.modelmedicines.com.

DANIEL HADERS II
CO-FOUNDER & CEO

Dr. Daniel Haders II is the Co-Founder and CEO of Model Medicines, a leading generative AI biotech company named to Fierce Medtech's "Fierce 15" and GEN's "Ten Companies to Watch in AI Drug Discovery." Recognized among "The Top 50 Healthcare AI Entrepreneurs of 2025" and featured in Bloomberg Intelligence's "Vanguards of Healthcare" series, he previously built one of the world's leading global digital health accelerators. A former pharmaceutical scientist at Lux Biosciences (developer of CEQUA®), Dr. Haders holds a PhD in Biomedical Engineering from Rutgers University and a BS from Columbia University, and has authored multiple patents and peer-reviewed manuscripts.

JOIN US IN BOSTON

MEET THE FINALISTS

NOVEMBER 18-20

THOMAS M. MENINO CONVENTION & EXHIBITION CENTER
415 SUMMER STREET
BOSTON, MA 02210,
UNITED STATES

PHARMA & BIOTECH PASS

FREE

A limited number of free passes are available to select professionals from pharmaceutical and biotechology companies. Please apply to be considered.

APPLY NOW

ACADEMICS & CHARITIES

$1,449

Standard Price

- A Teacher, Professor, Researcher or Scholar at a University or Higher Education Institute, registration to be completed with academic email address
- An organisation with NPO or Charitable Status

REGISTER NOW

PRE-SERIES B DRUG DEVELOPERS & SOLUTION PROVIDERS

Pre-Series B drug developers and solution providers offering early-stage therapeutics, enabling technologies, or services to support drug development

INQUIRE NOW

DRUG DEVELOPERS & INVESTORS

$2,449

Standard Price

- Must not be outsourcing pipeline
- Must not offer offer paid-for products and/or partnering services, including but not limited to: Consultants, CROs, CDMOs, Discovery Tool Providers and Equipment Manufacturers

REGISTER NOW

SOLUTION PROVIDERS

$3,999

Limited Passes Available

- Organisations that offer paid-for products and/or partnering services, including but not limited to: Consultants, CROs, CDMOs, Discovery Tool Providers and Equipment Manufacturers

REGISTER NOW